Oslo, 5 September 2022. Lytix Biopharma ("Lytix") (Euronext Growth Oslo: LYTIX),
a Norwegian immune-oncology company, today announces the appointment of Stephen
Worsley as Chief Business Officer (CBO).

Stephen Worsley is a pharmaceutical executive with over 25 years of experience
in business development leadership in roles of increasing impact and in
executing high-valuation strategic deals in the biopharmaceutical and drug
discovery/development market. As a business development executive, Worsley has
led negotiation of transformative and award-winning technology and product
partnerships for leading therapeutics companies.  

Most recently Stephen Worsley served as the Vice President Strategic Business
Development at Redwood Biosciences/ Catalent Pharma Services. Prior to that, he
was CBO at Sutro Biopharma, Sr. Vice President Business Development at
IndiMolecular and Vice President of Business Development at Peregrine
Pharmaceutical (dba Avid Pharma Services) amongst other roles in his career.


"As we plan for continued progress to reach several important milestones in our
development programs at Lytix, we are excited to welcome Stephen Worsley to our
management team at Lytix Biopharma", says Øystein Rekdal, CEO of Lytix. "His
extensive experience in business development where he has led various strategic
partnerships, acquisitions, equity investments, clinical collaborations, and out
licensing transactions will play a central role as we advance our exciting
pipeline of immuno-activating drugs for cancer through further clinical
development and towards market, with several potential partnering opportunities
along the way".

Stephen will enter his leading position at Lytix at September 6. With the
position as CBO, he will join Lytix' executive management team.

"I am very pleased to be joining the Lytix team at an exciting time for the
company as we develop a very promising new class of immuno-activating drugs for
the treatment of cancer" said Stephen Worsley "There is growing interest in the
platform and evolving clinical outcomes which will allow Lytix to consider
several value creating business development opportunities in the months and
years ahead."


For more information, please contact: 
Ole Peter Nordby, ole.peter.nordby@lytixbiopharma.com

Lytix Biopharma in brief: 
Based in Oslo, Norway, Lytix is a clinical stage biotech company developing
novel cancer immunotherapies, an area within cancer therapy that is aimed at
activating the patient's immune system to fight cancer. The company's technology
is based on pioneering research in "host defense peptides" - nature's first line
of defense towards foreign pathogens. Lytix Biopharma's lead product, LTX-315,
is a first-in-class oncolytic molecule representing a new and superior
therapeutic principle to boost anti-cancer immunity, with the potential to be
the ideal combination partner with other types of immunotherapies. LTX-315
targets cancer cells and disintegrates their cell membranes, causing immunogenic
cell death and release of a patient's tumor specific antigens and potent
immunostimulants. This mode of action allows cytotoxic T cells to recognize,
infiltrate and attack cancer cells.